Topics:

Treatment of Relapsed B-Cell Non-Hodgkin’s Lymphoma With a Combination of Chimeric Anti-CD20 Monoclonal Antibodies (Rituximab) and G-CSF: Final Report on Safety and Efficacy

Treatment of Relapsed B-Cell Non-Hodgkin’s Lymphoma With a Combination of Chimeric Anti-CD20 Monoclonal Antibodies (Rituximab) and G-CSF: Final Report on Safety and Efficacy

Possible mechanisms of action of the chimeric CD20 monoclonal antibody rituximab (Rituxan) involve complement- and antibody-dependent cellular cytotoxicity (ADCC). Because granulocyte colony-stimulating factor (G-CSF [Neupogen]) greatly enhances the cytotoxicity of neutrophils in ADCC, the clinical efficacy of rituximab might be enhanced by the addition of G-CSF. In a phase I/II clinical trial we investigated the safety and efficacy of the combination of rituximab and G-CSF in low-grade non-Hodgkin’s lymphoma (NHL) patients. Data on phase I have been reported before (Blood 92:4037a, 1998). Results of phase II will be presented.

Patients who had relapsed after a maximum of three prior systemic therapies received a total of four weekly intravenous doses of rituximab (375 mg/m2) in combination with a standard subcutaneous dose of G-CSF (5 µg/kg/d), administered for 3 days, starting 2 days before each infusion.

A total of 20 patients were treated with the combination of rituximab and G-CSF. Adverse events occurred almost exclusively during the first infusion and mainly consisted of (grade I/II) fever, chills, and allergic reactions. Toxicity was comparable to toxicity as reported for rituximab monotherapy.

Nineteen patients were evaluable for efficacy. The overall response rate was 42% (8/19; 95% confidence interval: 20%-67%). The percentages of complete remissions (CR) and partial remissions (PR) were 26% (5/19) and 16% (3/19), respectively. The median duration of response has not been reached at a median follow-up of 23 months. Only 1 patient who achieved a complete remission showed progressive disease (after 18 months); the other 4 patients are still in CR (for 13+, 24+, 25+, and 25+ months). In 4/5 patients that achieved a CR, remission duration was already considerably longer than achieved on last previous chemotherapy. The duration of partial remissions appeared to be shorter: 4, 10, and 4+ months, respectively.

CONCLUSION: The combination of rituximab and G-CSF is well-tolerated. Although the response rate seems comparable to that reported for rituximab monotherapy, remission duration in this small-sized phase II study is remarkably long. Randomized comparison with rituximab monotherapy should substantiate this promising finding.

Click here to read Dr. Bruce Cheson's commentary on this abstract.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.